Search company, investor...

Cardiosolutions

cardiosolutionsinc.com

Founded Year

2006

Stage

Series B | Dead

Total Raised

$25.57M

Last Raised

$15M

About Cardiosolutions

Cardiosolutions is a development stage company focused on a percutaneous alternative to open heart surgery to solve the problem of mitral regurgitation. The company is developing a technology, the Percu-Pro System, designed to deliver an implant that will provide a sealing surface for the leaflets of the mitral valve, thereby significantly reducing or eliminating mitral regurgitation (MR). Cardiosolutions' goal is to provide a new therapeutic alternative for a wide range of patients of all ages who suffer from moderate to severe mitral regurgitation, including a portion of those who are currently in congestive heart failure.

Headquarters Location

375 West Street

West Bridgewater, Massachusetts, 02379,

United States

781-344-0801

Missing: Cardiosolutions's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cardiosolutions's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Cardiosolutions

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cardiosolutions is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Cardiosolutions Patents

Cardiosolutions has filed 1 patent.

The 3 most popular patent topics include:

  • Cardiac anatomy
  • Cardiac surgery
  • Cardiac arrhythmia
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/16/2014

5/29/2018

Cardiac anatomy, Cardiac surgery, Valvular heart disease, Cardiology, Congenital heart defects

Grant

Application Date

6/16/2014

Grant Date

5/29/2018

Title

Related Topics

Cardiac anatomy, Cardiac surgery, Valvular heart disease, Cardiology, Congenital heart defects

Status

Grant

Latest Cardiosolutions News

Early Patient Cases with Mitra-Spacer™ System presented at PCR London Valves 2015

Sep 21, 2015

Early Patient Cases with Mitra-Spacer™ System presented at PCR London Valves 2015 2015-09-21 15:00 BERLIN and BOSTON, Sept. 21, 2015 /PRNewswire/ -- Cardiosolutions, Inc., a development stage company possessing a novel, atraumatic, volume adjustable, mitral valve therapeutic device, unveiled its first-in-human experience with the Mitra-Spacer™ System. The technological achievement was presented at PCR London Valves in Berlin, Germany. The proprietary Mitra-Spacer System is intended to treat or bridge heart failure patients whose operative mortality risk for undergoing conventional open-heart surgery is deemed too high. Cardiosolutions' pioneering technology involves the use of a tethered atraumatic inflatable and volume adjustable balloon placed between the anterior and posterior mitral valve leaflets via a trans-apical approach on the beating heart. The Mitra-Spacer System does not focus on the repair of various anatomical changes of the mitral valve but acts to fill the gap between the native leaflets, thus reducing the mitral regurgitation. The implant procedures were performed by Olaf Wendler MD, PhD, FRCS, Professor of Cardiac Surgery, King's College Hospital London, in selected patients on compassionate grounds. "A unique design feature of this promising technology is the ability to modify the fill volume of the Mitra-Spacer System post-procedure. This allows adjusting the mitral regurgitation therapy to the capacity of the left heart function and to eliminate residual mitral regurgitation in the long term course after implant", said Professor Olaf Wendler. Thomas Piemonte, MD FACC, FSCAI, Chief Medical Officer, Cardiosolutions, Inc. commented: "This challenging early clinical stage in very sick patients demonstrates the implant feasibility of the Mitra-Spacer System as well as the immediate performance of the device in reducing mitral regurgitation". "The first implants of the Mitra-Spacer System are an important step toward our goal of introducing a transformational therapy for the treatment of mitral regurgitation to provide patients with an alternative, less invasive treatment option", said Steven Tallarida, Chairman, Cardiosolutions, Inc. About Mitral Regurgitation Today two to three percent of the world's population suffers from mitral regurgitation and approximately 2.3 million patients in the US and Europe suffer from severe mitral regurgitation. Every year approximately 500,000 new patients are diagnosed with this disease, of which over 80% are untreated. A substantial group of patients have no option because they are too sick to survive the surgery and many others delay treatment because they have only moderate symptoms. About Cardiosolutions Cardiosolutions, Inc. ( www.cardiosolutionsinc.com ) is developing a less invasive alternative to open heart surgical repair of the mitral valve. The Cardiosolutions Mitra-Spacer System is designed to provide a therapeutic substitute to this complicated open heart valve repair procedure. Cardiosolutions was incubated and spun out of Primo Medical Group, Inc. (Stoughton MA. ) partnering with BioVentures Investors ( www.bioventuresinvestors.com ), a leading Medtech venture firm and Sorin Group ( www.sorin.com ), a global medical device company and a leader in the treatment of cardiovascular diseases. For more information, please visit www.cardiosolutionsinc.com , or contact: Ron Murphy 

Cardiosolutions Frequently Asked Questions (FAQ)

  • When was Cardiosolutions founded?

    Cardiosolutions was founded in 2006.

  • Where is Cardiosolutions's headquarters?

    Cardiosolutions's headquarters is located at 375 West Street, West Bridgewater.

  • What is Cardiosolutions's latest funding round?

    Cardiosolutions's latest funding round is Series B.

  • How much did Cardiosolutions raise?

    Cardiosolutions raised a total of $25.57M.

  • Who are the investors of Cardiosolutions?

    Investors of Cardiosolutions include LivaNova, BioVentures Investors and Primo Medical Group.

  • Who are Cardiosolutions's competitors?

    Competitors of Cardiosolutions include NeoChord, Ancora Heart, Vertos Medical, Cardiac Dimensions, TherOx, Mitralign, CardiAQ Valve Technologies, Bioconnect Systems, Endovalve, CardioPolymers and 12 more.

Compare Cardiosolutions to Competitors

NeoChord Logo
NeoChord

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.

Cardiac Dimensions Logo
Cardiac Dimensions

Cardiac Dimensions develops minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company's initial technology platform, the CARILLON Mitral Contour System has been designed to address functional mitral regurgitation, utilizing a novel percutaneous approach. Cardiac Dimensions has operations in Kirkland, Washington; Sydney, Australia and Frankfurt, Germany.

C
CoRepair

CoRepair, Inc. is developing a radiofrequency (RF) device system for the treatment of congestive heart failure.

Mitralign Logo
Mitralign

Mitralign is developing a catheter-based technology for percutaneous treatment of functional mitral regurgitation. The Mitralign system emulates surgical annuloplasty delivering a series of surgical implants directly into the mitral annulus by means of a catheter. The implants are cinched together, thus reducing the size of the mitral valve annulus and the valve opening.

V
Viacor

Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of congestive heart failure.

Cardious Logo
Cardious

Cardious is a medical device company organized to develop and commercialize the AvA Aortic Valve Bypass Graft System for use as a minimally invasive, beating heart alternative to traditional aortic valve replacement therapy.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.